Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD
Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (...
Ausführliche Beschreibung
Autor*in: |
Ziad A. Massy [verfasserIn] Jean Ferrières [verfasserIn] Eric Bruckert [verfasserIn] Céline Lange [verfasserIn] Sophie Liabeuf [verfasserIn] Maja Velkovski-Rouyer [verfasserIn] Bénédicte Stengel [verfasserIn] Carole Ayav [verfasserIn] Christian Combe [verfasserIn] Denis Fouque [verfasserIn] Luc Frimat [verfasserIn] Yves-Edouard Herpe [verfasserIn] Maurice Laville [verfasserIn] Ziad Massy [verfasserIn] Karine Legrand [verfasserIn] Marie Metzger [verfasserIn] Elodie Speyer [verfasserIn] Bruno Moulin [verfasserIn] Gaétan Lebrun [verfasserIn] Éric Magnant [verfasserIn] Gabriel Choukroun [verfasserIn] Jean Philippe Bourdenx [verfasserIn] Marie Essig [verfasserIn] Raymond Azar [verfasserIn] Mustafa Smati [verfasserIn] Mohamed Jamali [verfasserIn] Alexandre Klein [verfasserIn] Michel Delahousse [verfasserIn] Séverine Martin [verfasserIn] Eric Thervet [verfasserIn] Xavier Belenfant [verfasserIn] Pablo Urena [verfasserIn] Carlos Vela [verfasserIn] Dominique Chauveau [verfasserIn] Viktor Panescu [verfasserIn] François Glowacki [verfasserIn] Maxime Hoffmann [verfasserIn] Maryvonne Hourmant [verfasserIn] Dominique Besnier [verfasserIn] Angelo Testa [verfasserIn] Philippe Zaoui [verfasserIn] Charles Chazot [verfasserIn] Laurent Juillard [verfasserIn] Stéphane Burtey [verfasserIn] Adrien Keller [verfasserIn] Nassim Kamar [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2019 |
---|
Übergeordnetes Werk: |
In: Kidney International Reports - Elsevier, 2016, 4(2019), 11, Seite 1546-1554 |
---|---|
Übergeordnetes Werk: |
volume:4 ; year:2019 ; number:11 ; pages:1546-1554 |
Links: |
---|
DOI / URN: |
10.1016/j.ekir.2019.07.014 |
---|
Katalog-ID: |
DOAJ049324918 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ049324918 | ||
003 | DE-627 | ||
005 | 20230308142626.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ekir.2019.07.014 |2 doi | |
035 | |a (DE-627)DOAJ049324918 | ||
035 | |a (DE-599)DOAJ2e2d670b48f24d0da27d45f04c41f401 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC870-923 | |
100 | 0 | |a Ziad A. Massy |e verfasserin |4 aut | |
245 | 1 | 0 | |a Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol | ||
653 | 0 | |a Diseases of the genitourinary system. Urology | |
700 | 0 | |a Jean Ferrières |e verfasserin |4 aut | |
700 | 0 | |a Eric Bruckert |e verfasserin |4 aut | |
700 | 0 | |a Céline Lange |e verfasserin |4 aut | |
700 | 0 | |a Sophie Liabeuf |e verfasserin |4 aut | |
700 | 0 | |a Maja Velkovski-Rouyer |e verfasserin |4 aut | |
700 | 0 | |a Bénédicte Stengel |e verfasserin |4 aut | |
700 | 0 | |a Carole Ayav |e verfasserin |4 aut | |
700 | 0 | |a Christian Combe |e verfasserin |4 aut | |
700 | 0 | |a Denis Fouque |e verfasserin |4 aut | |
700 | 0 | |a Luc Frimat |e verfasserin |4 aut | |
700 | 0 | |a Yves-Edouard Herpe |e verfasserin |4 aut | |
700 | 0 | |a Maurice Laville |e verfasserin |4 aut | |
700 | 0 | |a Ziad Massy |e verfasserin |4 aut | |
700 | 0 | |a Bénédicte Stengel |e verfasserin |4 aut | |
700 | 0 | |a Céline Lange |e verfasserin |4 aut | |
700 | 0 | |a Karine Legrand |e verfasserin |4 aut | |
700 | 0 | |a Sophie Liabeuf |e verfasserin |4 aut | |
700 | 0 | |a Marie Metzger |e verfasserin |4 aut | |
700 | 0 | |a Elodie Speyer |e verfasserin |4 aut | |
700 | 0 | |a Bruno Moulin |e verfasserin |4 aut | |
700 | 0 | |a Gaétan Lebrun |e verfasserin |4 aut | |
700 | 0 | |a Éric Magnant |e verfasserin |4 aut | |
700 | 0 | |a Gabriel Choukroun |e verfasserin |4 aut | |
700 | 0 | |a Jean Philippe Bourdenx |e verfasserin |4 aut | |
700 | 0 | |a Marie Essig |e verfasserin |4 aut | |
700 | 0 | |a Raymond Azar |e verfasserin |4 aut | |
700 | 0 | |a Mustafa Smati |e verfasserin |4 aut | |
700 | 0 | |a Mohamed Jamali |e verfasserin |4 aut | |
700 | 0 | |a Alexandre Klein |e verfasserin |4 aut | |
700 | 0 | |a Michel Delahousse |e verfasserin |4 aut | |
700 | 0 | |a Christian Combe |e verfasserin |4 aut | |
700 | 0 | |a Séverine Martin |e verfasserin |4 aut | |
700 | 0 | |a Eric Thervet |e verfasserin |4 aut | |
700 | 0 | |a Ziad Massy |e verfasserin |4 aut | |
700 | 0 | |a Xavier Belenfant |e verfasserin |4 aut | |
700 | 0 | |a Pablo Urena |e verfasserin |4 aut | |
700 | 0 | |a Carlos Vela |e verfasserin |4 aut | |
700 | 0 | |a Luc Frimat |e verfasserin |4 aut | |
700 | 0 | |a Dominique Chauveau |e verfasserin |4 aut | |
700 | 0 | |a Viktor Panescu |e verfasserin |4 aut | |
700 | 0 | |a François Glowacki |e verfasserin |4 aut | |
700 | 0 | |a Maxime Hoffmann |e verfasserin |4 aut | |
700 | 0 | |a Maryvonne Hourmant |e verfasserin |4 aut | |
700 | 0 | |a Dominique Besnier |e verfasserin |4 aut | |
700 | 0 | |a Angelo Testa |e verfasserin |4 aut | |
700 | 0 | |a Philippe Zaoui |e verfasserin |4 aut | |
700 | 0 | |a Charles Chazot |e verfasserin |4 aut | |
700 | 0 | |a Laurent Juillard |e verfasserin |4 aut | |
700 | 0 | |a Stéphane Burtey |e verfasserin |4 aut | |
700 | 0 | |a Adrien Keller |e verfasserin |4 aut | |
700 | 0 | |a Nassim Kamar |e verfasserin |4 aut | |
700 | 0 | |a Denis Fouque |e verfasserin |4 aut | |
700 | 0 | |a Maurice Laville |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Kidney International Reports |d Elsevier, 2016 |g 4(2019), 11, Seite 1546-1554 |w (DE-627)881695580 |w (DE-600)2887223-X |x 24680249 |7 nnns |
773 | 1 | 8 | |g volume:4 |g year:2019 |g number:11 |g pages:1546-1554 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.ekir.2019.07.014 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/2e2d670b48f24d0da27d45f04c41f401 |z kostenfrei |
856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2468024919314354 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2468-0249 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 4 |j 2019 |e 11 |h 1546-1554 |
author_variant |
z a m zam j f jf e b eb c l cl s l sl m v r mvr b s bs c a ca c c cc d f df l f lf y e h yeh m l ml z m zm b s bs c l cl k l kl s l sl m m mm e s es b m bm g l gl é m ém g c gc j p b jpb m e me r a ra m s ms m j mj a k ak m d md c c cc s m sm e t et z m zm x b xb p u pu c v cv l f lf d c dc v p vp f g fg m h mh m h mh d b db a t at p z pz c c cc l j lj s b sb a k ak n k nk d f df m l ml |
---|---|
matchkey_str |
article:24680249:2019----::civmnolwestlppoenhlse |
hierarchy_sort_str |
2019 |
callnumber-subject-code |
RC |
publishDate |
2019 |
allfields |
10.1016/j.ekir.2019.07.014 doi (DE-627)DOAJ049324918 (DE-599)DOAJ2e2d670b48f24d0da27d45f04c41f401 DE-627 ger DE-627 rakwb eng RC870-923 Ziad A. Massy verfasserin aut Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol Diseases of the genitourinary system. Urology Jean Ferrières verfasserin aut Eric Bruckert verfasserin aut Céline Lange verfasserin aut Sophie Liabeuf verfasserin aut Maja Velkovski-Rouyer verfasserin aut Bénédicte Stengel verfasserin aut Carole Ayav verfasserin aut Christian Combe verfasserin aut Denis Fouque verfasserin aut Luc Frimat verfasserin aut Yves-Edouard Herpe verfasserin aut Maurice Laville verfasserin aut Ziad Massy verfasserin aut Bénédicte Stengel verfasserin aut Céline Lange verfasserin aut Karine Legrand verfasserin aut Sophie Liabeuf verfasserin aut Marie Metzger verfasserin aut Elodie Speyer verfasserin aut Bruno Moulin verfasserin aut Gaétan Lebrun verfasserin aut Éric Magnant verfasserin aut Gabriel Choukroun verfasserin aut Jean Philippe Bourdenx verfasserin aut Marie Essig verfasserin aut Raymond Azar verfasserin aut Mustafa Smati verfasserin aut Mohamed Jamali verfasserin aut Alexandre Klein verfasserin aut Michel Delahousse verfasserin aut Christian Combe verfasserin aut Séverine Martin verfasserin aut Eric Thervet verfasserin aut Ziad Massy verfasserin aut Xavier Belenfant verfasserin aut Pablo Urena verfasserin aut Carlos Vela verfasserin aut Luc Frimat verfasserin aut Dominique Chauveau verfasserin aut Viktor Panescu verfasserin aut François Glowacki verfasserin aut Maxime Hoffmann verfasserin aut Maryvonne Hourmant verfasserin aut Dominique Besnier verfasserin aut Angelo Testa verfasserin aut Philippe Zaoui verfasserin aut Charles Chazot verfasserin aut Laurent Juillard verfasserin aut Stéphane Burtey verfasserin aut Adrien Keller verfasserin aut Nassim Kamar verfasserin aut Denis Fouque verfasserin aut Maurice Laville verfasserin aut In Kidney International Reports Elsevier, 2016 4(2019), 11, Seite 1546-1554 (DE-627)881695580 (DE-600)2887223-X 24680249 nnns volume:4 year:2019 number:11 pages:1546-1554 https://doi.org/10.1016/j.ekir.2019.07.014 kostenfrei https://doaj.org/article/2e2d670b48f24d0da27d45f04c41f401 kostenfrei http://www.sciencedirect.com/science/article/pii/S2468024919314354 kostenfrei https://doaj.org/toc/2468-0249 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 4 2019 11 1546-1554 |
spelling |
10.1016/j.ekir.2019.07.014 doi (DE-627)DOAJ049324918 (DE-599)DOAJ2e2d670b48f24d0da27d45f04c41f401 DE-627 ger DE-627 rakwb eng RC870-923 Ziad A. Massy verfasserin aut Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol Diseases of the genitourinary system. Urology Jean Ferrières verfasserin aut Eric Bruckert verfasserin aut Céline Lange verfasserin aut Sophie Liabeuf verfasserin aut Maja Velkovski-Rouyer verfasserin aut Bénédicte Stengel verfasserin aut Carole Ayav verfasserin aut Christian Combe verfasserin aut Denis Fouque verfasserin aut Luc Frimat verfasserin aut Yves-Edouard Herpe verfasserin aut Maurice Laville verfasserin aut Ziad Massy verfasserin aut Bénédicte Stengel verfasserin aut Céline Lange verfasserin aut Karine Legrand verfasserin aut Sophie Liabeuf verfasserin aut Marie Metzger verfasserin aut Elodie Speyer verfasserin aut Bruno Moulin verfasserin aut Gaétan Lebrun verfasserin aut Éric Magnant verfasserin aut Gabriel Choukroun verfasserin aut Jean Philippe Bourdenx verfasserin aut Marie Essig verfasserin aut Raymond Azar verfasserin aut Mustafa Smati verfasserin aut Mohamed Jamali verfasserin aut Alexandre Klein verfasserin aut Michel Delahousse verfasserin aut Christian Combe verfasserin aut Séverine Martin verfasserin aut Eric Thervet verfasserin aut Ziad Massy verfasserin aut Xavier Belenfant verfasserin aut Pablo Urena verfasserin aut Carlos Vela verfasserin aut Luc Frimat verfasserin aut Dominique Chauveau verfasserin aut Viktor Panescu verfasserin aut François Glowacki verfasserin aut Maxime Hoffmann verfasserin aut Maryvonne Hourmant verfasserin aut Dominique Besnier verfasserin aut Angelo Testa verfasserin aut Philippe Zaoui verfasserin aut Charles Chazot verfasserin aut Laurent Juillard verfasserin aut Stéphane Burtey verfasserin aut Adrien Keller verfasserin aut Nassim Kamar verfasserin aut Denis Fouque verfasserin aut Maurice Laville verfasserin aut In Kidney International Reports Elsevier, 2016 4(2019), 11, Seite 1546-1554 (DE-627)881695580 (DE-600)2887223-X 24680249 nnns volume:4 year:2019 number:11 pages:1546-1554 https://doi.org/10.1016/j.ekir.2019.07.014 kostenfrei https://doaj.org/article/2e2d670b48f24d0da27d45f04c41f401 kostenfrei http://www.sciencedirect.com/science/article/pii/S2468024919314354 kostenfrei https://doaj.org/toc/2468-0249 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 4 2019 11 1546-1554 |
allfields_unstemmed |
10.1016/j.ekir.2019.07.014 doi (DE-627)DOAJ049324918 (DE-599)DOAJ2e2d670b48f24d0da27d45f04c41f401 DE-627 ger DE-627 rakwb eng RC870-923 Ziad A. Massy verfasserin aut Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol Diseases of the genitourinary system. Urology Jean Ferrières verfasserin aut Eric Bruckert verfasserin aut Céline Lange verfasserin aut Sophie Liabeuf verfasserin aut Maja Velkovski-Rouyer verfasserin aut Bénédicte Stengel verfasserin aut Carole Ayav verfasserin aut Christian Combe verfasserin aut Denis Fouque verfasserin aut Luc Frimat verfasserin aut Yves-Edouard Herpe verfasserin aut Maurice Laville verfasserin aut Ziad Massy verfasserin aut Bénédicte Stengel verfasserin aut Céline Lange verfasserin aut Karine Legrand verfasserin aut Sophie Liabeuf verfasserin aut Marie Metzger verfasserin aut Elodie Speyer verfasserin aut Bruno Moulin verfasserin aut Gaétan Lebrun verfasserin aut Éric Magnant verfasserin aut Gabriel Choukroun verfasserin aut Jean Philippe Bourdenx verfasserin aut Marie Essig verfasserin aut Raymond Azar verfasserin aut Mustafa Smati verfasserin aut Mohamed Jamali verfasserin aut Alexandre Klein verfasserin aut Michel Delahousse verfasserin aut Christian Combe verfasserin aut Séverine Martin verfasserin aut Eric Thervet verfasserin aut Ziad Massy verfasserin aut Xavier Belenfant verfasserin aut Pablo Urena verfasserin aut Carlos Vela verfasserin aut Luc Frimat verfasserin aut Dominique Chauveau verfasserin aut Viktor Panescu verfasserin aut François Glowacki verfasserin aut Maxime Hoffmann verfasserin aut Maryvonne Hourmant verfasserin aut Dominique Besnier verfasserin aut Angelo Testa verfasserin aut Philippe Zaoui verfasserin aut Charles Chazot verfasserin aut Laurent Juillard verfasserin aut Stéphane Burtey verfasserin aut Adrien Keller verfasserin aut Nassim Kamar verfasserin aut Denis Fouque verfasserin aut Maurice Laville verfasserin aut In Kidney International Reports Elsevier, 2016 4(2019), 11, Seite 1546-1554 (DE-627)881695580 (DE-600)2887223-X 24680249 nnns volume:4 year:2019 number:11 pages:1546-1554 https://doi.org/10.1016/j.ekir.2019.07.014 kostenfrei https://doaj.org/article/2e2d670b48f24d0da27d45f04c41f401 kostenfrei http://www.sciencedirect.com/science/article/pii/S2468024919314354 kostenfrei https://doaj.org/toc/2468-0249 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 4 2019 11 1546-1554 |
allfieldsGer |
10.1016/j.ekir.2019.07.014 doi (DE-627)DOAJ049324918 (DE-599)DOAJ2e2d670b48f24d0da27d45f04c41f401 DE-627 ger DE-627 rakwb eng RC870-923 Ziad A. Massy verfasserin aut Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol Diseases of the genitourinary system. Urology Jean Ferrières verfasserin aut Eric Bruckert verfasserin aut Céline Lange verfasserin aut Sophie Liabeuf verfasserin aut Maja Velkovski-Rouyer verfasserin aut Bénédicte Stengel verfasserin aut Carole Ayav verfasserin aut Christian Combe verfasserin aut Denis Fouque verfasserin aut Luc Frimat verfasserin aut Yves-Edouard Herpe verfasserin aut Maurice Laville verfasserin aut Ziad Massy verfasserin aut Bénédicte Stengel verfasserin aut Céline Lange verfasserin aut Karine Legrand verfasserin aut Sophie Liabeuf verfasserin aut Marie Metzger verfasserin aut Elodie Speyer verfasserin aut Bruno Moulin verfasserin aut Gaétan Lebrun verfasserin aut Éric Magnant verfasserin aut Gabriel Choukroun verfasserin aut Jean Philippe Bourdenx verfasserin aut Marie Essig verfasserin aut Raymond Azar verfasserin aut Mustafa Smati verfasserin aut Mohamed Jamali verfasserin aut Alexandre Klein verfasserin aut Michel Delahousse verfasserin aut Christian Combe verfasserin aut Séverine Martin verfasserin aut Eric Thervet verfasserin aut Ziad Massy verfasserin aut Xavier Belenfant verfasserin aut Pablo Urena verfasserin aut Carlos Vela verfasserin aut Luc Frimat verfasserin aut Dominique Chauveau verfasserin aut Viktor Panescu verfasserin aut François Glowacki verfasserin aut Maxime Hoffmann verfasserin aut Maryvonne Hourmant verfasserin aut Dominique Besnier verfasserin aut Angelo Testa verfasserin aut Philippe Zaoui verfasserin aut Charles Chazot verfasserin aut Laurent Juillard verfasserin aut Stéphane Burtey verfasserin aut Adrien Keller verfasserin aut Nassim Kamar verfasserin aut Denis Fouque verfasserin aut Maurice Laville verfasserin aut In Kidney International Reports Elsevier, 2016 4(2019), 11, Seite 1546-1554 (DE-627)881695580 (DE-600)2887223-X 24680249 nnns volume:4 year:2019 number:11 pages:1546-1554 https://doi.org/10.1016/j.ekir.2019.07.014 kostenfrei https://doaj.org/article/2e2d670b48f24d0da27d45f04c41f401 kostenfrei http://www.sciencedirect.com/science/article/pii/S2468024919314354 kostenfrei https://doaj.org/toc/2468-0249 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 4 2019 11 1546-1554 |
allfieldsSound |
10.1016/j.ekir.2019.07.014 doi (DE-627)DOAJ049324918 (DE-599)DOAJ2e2d670b48f24d0da27d45f04c41f401 DE-627 ger DE-627 rakwb eng RC870-923 Ziad A. Massy verfasserin aut Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol Diseases of the genitourinary system. Urology Jean Ferrières verfasserin aut Eric Bruckert verfasserin aut Céline Lange verfasserin aut Sophie Liabeuf verfasserin aut Maja Velkovski-Rouyer verfasserin aut Bénédicte Stengel verfasserin aut Carole Ayav verfasserin aut Christian Combe verfasserin aut Denis Fouque verfasserin aut Luc Frimat verfasserin aut Yves-Edouard Herpe verfasserin aut Maurice Laville verfasserin aut Ziad Massy verfasserin aut Bénédicte Stengel verfasserin aut Céline Lange verfasserin aut Karine Legrand verfasserin aut Sophie Liabeuf verfasserin aut Marie Metzger verfasserin aut Elodie Speyer verfasserin aut Bruno Moulin verfasserin aut Gaétan Lebrun verfasserin aut Éric Magnant verfasserin aut Gabriel Choukroun verfasserin aut Jean Philippe Bourdenx verfasserin aut Marie Essig verfasserin aut Raymond Azar verfasserin aut Mustafa Smati verfasserin aut Mohamed Jamali verfasserin aut Alexandre Klein verfasserin aut Michel Delahousse verfasserin aut Christian Combe verfasserin aut Séverine Martin verfasserin aut Eric Thervet verfasserin aut Ziad Massy verfasserin aut Xavier Belenfant verfasserin aut Pablo Urena verfasserin aut Carlos Vela verfasserin aut Luc Frimat verfasserin aut Dominique Chauveau verfasserin aut Viktor Panescu verfasserin aut François Glowacki verfasserin aut Maxime Hoffmann verfasserin aut Maryvonne Hourmant verfasserin aut Dominique Besnier verfasserin aut Angelo Testa verfasserin aut Philippe Zaoui verfasserin aut Charles Chazot verfasserin aut Laurent Juillard verfasserin aut Stéphane Burtey verfasserin aut Adrien Keller verfasserin aut Nassim Kamar verfasserin aut Denis Fouque verfasserin aut Maurice Laville verfasserin aut In Kidney International Reports Elsevier, 2016 4(2019), 11, Seite 1546-1554 (DE-627)881695580 (DE-600)2887223-X 24680249 nnns volume:4 year:2019 number:11 pages:1546-1554 https://doi.org/10.1016/j.ekir.2019.07.014 kostenfrei https://doaj.org/article/2e2d670b48f24d0da27d45f04c41f401 kostenfrei http://www.sciencedirect.com/science/article/pii/S2468024919314354 kostenfrei https://doaj.org/toc/2468-0249 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 AR 4 2019 11 1546-1554 |
language |
English |
source |
In Kidney International Reports 4(2019), 11, Seite 1546-1554 volume:4 year:2019 number:11 pages:1546-1554 |
sourceStr |
In Kidney International Reports 4(2019), 11, Seite 1546-1554 volume:4 year:2019 number:11 pages:1546-1554 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Diseases of the genitourinary system. Urology |
isfreeaccess_bool |
true |
container_title |
Kidney International Reports |
authorswithroles_txt_mv |
Ziad A. Massy @@aut@@ Jean Ferrières @@aut@@ Eric Bruckert @@aut@@ Céline Lange @@aut@@ Sophie Liabeuf @@aut@@ Maja Velkovski-Rouyer @@aut@@ Bénédicte Stengel @@aut@@ Carole Ayav @@aut@@ Christian Combe @@aut@@ Denis Fouque @@aut@@ Luc Frimat @@aut@@ Yves-Edouard Herpe @@aut@@ Maurice Laville @@aut@@ Ziad Massy @@aut@@ Karine Legrand @@aut@@ Marie Metzger @@aut@@ Elodie Speyer @@aut@@ Bruno Moulin @@aut@@ Gaétan Lebrun @@aut@@ Éric Magnant @@aut@@ Gabriel Choukroun @@aut@@ Jean Philippe Bourdenx @@aut@@ Marie Essig @@aut@@ Raymond Azar @@aut@@ Mustafa Smati @@aut@@ Mohamed Jamali @@aut@@ Alexandre Klein @@aut@@ Michel Delahousse @@aut@@ Séverine Martin @@aut@@ Eric Thervet @@aut@@ Xavier Belenfant @@aut@@ Pablo Urena @@aut@@ Carlos Vela @@aut@@ Dominique Chauveau @@aut@@ Viktor Panescu @@aut@@ François Glowacki @@aut@@ Maxime Hoffmann @@aut@@ Maryvonne Hourmant @@aut@@ Dominique Besnier @@aut@@ Angelo Testa @@aut@@ Philippe Zaoui @@aut@@ Charles Chazot @@aut@@ Laurent Juillard @@aut@@ Stéphane Burtey @@aut@@ Adrien Keller @@aut@@ Nassim Kamar @@aut@@ |
publishDateDaySort_date |
2019-01-01T00:00:00Z |
hierarchy_top_id |
881695580 |
id |
DOAJ049324918 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ049324918</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308142626.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ekir.2019.07.014</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ049324918</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2e2d670b48f24d0da27d45f04c41f401</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ziad A. Massy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jean Ferrières</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eric Bruckert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Céline Lange</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sophie Liabeuf</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maja Velkovski-Rouyer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bénédicte Stengel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carole Ayav</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christian Combe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denis Fouque</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luc Frimat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yves-Edouard Herpe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurice Laville</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ziad Massy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bénédicte Stengel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Céline Lange</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Karine Legrand</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sophie Liabeuf</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marie Metzger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elodie Speyer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bruno Moulin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gaétan Lebrun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Éric Magnant</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gabriel Choukroun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jean Philippe Bourdenx</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marie Essig</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Raymond Azar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mustafa Smati</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohamed Jamali</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexandre Klein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michel Delahousse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christian Combe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Séverine Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eric Thervet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ziad Massy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xavier Belenfant</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo Urena</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carlos Vela</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luc Frimat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dominique Chauveau</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Viktor Panescu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">François Glowacki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maxime Hoffmann</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maryvonne Hourmant</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dominique Besnier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angelo Testa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Philippe Zaoui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Charles Chazot</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laurent Juillard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stéphane Burtey</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adrien Keller</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nassim Kamar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denis Fouque</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurice Laville</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Kidney International Reports</subfield><subfield code="d">Elsevier, 2016</subfield><subfield code="g">4(2019), 11, Seite 1546-1554</subfield><subfield code="w">(DE-627)881695580</subfield><subfield code="w">(DE-600)2887223-X</subfield><subfield code="x">24680249</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1546-1554</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ekir.2019.07.014</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2e2d670b48f24d0da27d45f04c41f401</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2468024919314354</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2468-0249</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2019</subfield><subfield code="e">11</subfield><subfield code="h">1546-1554</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Ziad A. Massy |
spellingShingle |
Ziad A. Massy misc RC870-923 misc Diseases of the genitourinary system. Urology Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
authorStr |
Ziad A. Massy |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)881695580 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC870-923 |
illustrated |
Not Illustrated |
issn |
24680249 |
topic_title |
RC870-923 Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
topic |
misc RC870-923 misc Diseases of the genitourinary system. Urology |
topic_unstemmed |
misc RC870-923 misc Diseases of the genitourinary system. Urology |
topic_browse |
misc RC870-923 misc Diseases of the genitourinary system. Urology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Kidney International Reports |
hierarchy_parent_id |
881695580 |
hierarchy_top_title |
Kidney International Reports |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)881695580 (DE-600)2887223-X |
title |
Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
ctrlnum |
(DE-627)DOAJ049324918 (DE-599)DOAJ2e2d670b48f24d0da27d45f04c41f401 |
title_full |
Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
author_sort |
Ziad A. Massy |
journal |
Kidney International Reports |
journalStr |
Kidney International Reports |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2019 |
contenttype_str_mv |
txt |
container_start_page |
1546 |
author_browse |
Ziad A. Massy Jean Ferrières Eric Bruckert Céline Lange Sophie Liabeuf Maja Velkovski-Rouyer Bénédicte Stengel Carole Ayav Christian Combe Denis Fouque Luc Frimat Yves-Edouard Herpe Maurice Laville Ziad Massy Karine Legrand Marie Metzger Elodie Speyer Bruno Moulin Gaétan Lebrun Éric Magnant Gabriel Choukroun Jean Philippe Bourdenx Marie Essig Raymond Azar Mustafa Smati Mohamed Jamali Alexandre Klein Michel Delahousse Séverine Martin Eric Thervet Xavier Belenfant Pablo Urena Carlos Vela Dominique Chauveau Viktor Panescu François Glowacki Maxime Hoffmann Maryvonne Hourmant Dominique Besnier Angelo Testa Philippe Zaoui Charles Chazot Laurent Juillard Stéphane Burtey Adrien Keller Nassim Kamar |
container_volume |
4 |
class |
RC870-923 |
format_se |
Elektronische Aufsätze |
author-letter |
Ziad A. Massy |
doi_str_mv |
10.1016/j.ekir.2019.07.014 |
author2-role |
verfasserin |
title_sort |
achievement of low-density lipoprotein cholesterol targets in ckd |
callnumber |
RC870-923 |
title_auth |
Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
abstract |
Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol |
abstractGer |
Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol |
abstract_unstemmed |
Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2038 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4393 GBV_ILN_4700 |
container_issue |
11 |
title_short |
Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD |
url |
https://doi.org/10.1016/j.ekir.2019.07.014 https://doaj.org/article/2e2d670b48f24d0da27d45f04c41f401 http://www.sciencedirect.com/science/article/pii/S2468024919314354 https://doaj.org/toc/2468-0249 |
remote_bool |
true |
author2 |
Jean Ferrières Eric Bruckert Céline Lange Sophie Liabeuf Maja Velkovski-Rouyer Bénédicte Stengel Carole Ayav Christian Combe Denis Fouque Luc Frimat Yves-Edouard Herpe Maurice Laville Ziad Massy Karine Legrand Marie Metzger Elodie Speyer Bruno Moulin Gaétan Lebrun Éric Magnant Gabriel Choukroun Jean Philippe Bourdenx Marie Essig Raymond Azar Mustafa Smati Mohamed Jamali Alexandre Klein Michel Delahousse Séverine Martin Eric Thervet Xavier Belenfant Pablo Urena Carlos Vela Dominique Chauveau Viktor Panescu François Glowacki Maxime Hoffmann Maryvonne Hourmant Dominique Besnier Angelo Testa Philippe Zaoui Charles Chazot Laurent Juillard Stéphane Burtey Adrien Keller Nassim Kamar |
author2Str |
Jean Ferrières Eric Bruckert Céline Lange Sophie Liabeuf Maja Velkovski-Rouyer Bénédicte Stengel Carole Ayav Christian Combe Denis Fouque Luc Frimat Yves-Edouard Herpe Maurice Laville Ziad Massy Karine Legrand Marie Metzger Elodie Speyer Bruno Moulin Gaétan Lebrun Éric Magnant Gabriel Choukroun Jean Philippe Bourdenx Marie Essig Raymond Azar Mustafa Smati Mohamed Jamali Alexandre Klein Michel Delahousse Séverine Martin Eric Thervet Xavier Belenfant Pablo Urena Carlos Vela Dominique Chauveau Viktor Panescu François Glowacki Maxime Hoffmann Maryvonne Hourmant Dominique Besnier Angelo Testa Philippe Zaoui Charles Chazot Laurent Juillard Stéphane Burtey Adrien Keller Nassim Kamar |
ppnlink |
881695580 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1016/j.ekir.2019.07.014 |
callnumber-a |
RC870-923 |
up_date |
2024-07-03T22:44:31.991Z |
_version_ |
1803599659132780544 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ049324918</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308142626.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ekir.2019.07.014</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ049324918</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2e2d670b48f24d0da27d45f04c41f401</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ziad A. Massy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Introduction: We describe the characteristics of patients with moderate/advanced chronic kidney disease (CKD) according to receipt of lipid-lowering therapy (LLT), and whether they achieved low-density lipoprotein cholesterol (LDL-C) targets for high- and very high-risk patients. Methods: CKD-REIN (NCT03381950), a prospective cohort study conducted in 40 nephrology clinics in France, enrolled 3033 patients with moderate (stage G3) or advanced (stage G4/G5) CKD (2013−2016) who had not been on chronic dialysis or undergone kidney transplantation. Data were collected from patients’ interviews and medical records. Patients were followed up at 1 year. Results: Among 2542 patients (mean [SD] age 67 [13] years, 34% women) with LDL-C measurements at baseline (mean [SD] LDL-C 2.7 [1.1] mmol/l; cholesterol 4.8 [1.3] mmol/l), 63% were on LLT; 24% were at high (CKD stage G3, no cardiovascular disease [CVD] or diabetes) and 74% at very high (CKD stage G3 with diabetes or CVD, or CKD stage G4/5) cardiovascular risk. Among high-risk patients, 45% of those on statin and/or ezetimibe achieved the LDL-C treatment target (<2.6 mmol/l). Among very high-risk patients, the percentage at goal (<1.8 mmol/l) was 38% for CKD stage G3 and 29% for stage G4/5. There was a trend toward higher achievement of LDL-C targets with increasing LLT intensity (adjusted odds ratios for moderate vs. low intensity 1.20; 95% confidence interval 0.92–1.56; high vs. low intensity 1.46; 1.02–2.09; Ptrend = 0.036). Conclusion: Many patients with CKD stage G3−G5 who are eligible for LLT are not treated, and those on LLT rarely achieve LDL-C targets. Keywords: cardiovascular disease, chronic kidney diseases, lipid-regulating agents, lipids, low-density lipoprotein cholesterol</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jean Ferrières</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eric Bruckert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Céline Lange</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sophie Liabeuf</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maja Velkovski-Rouyer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bénédicte Stengel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carole Ayav</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christian Combe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denis Fouque</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luc Frimat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yves-Edouard Herpe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurice Laville</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ziad Massy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bénédicte Stengel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Céline Lange</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Karine Legrand</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sophie Liabeuf</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marie Metzger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elodie Speyer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bruno Moulin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gaétan Lebrun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Éric Magnant</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gabriel Choukroun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jean Philippe Bourdenx</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marie Essig</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Raymond Azar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mustafa Smati</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mohamed Jamali</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexandre Klein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michel Delahousse</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christian Combe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Séverine Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Eric Thervet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ziad Massy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xavier Belenfant</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pablo Urena</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Carlos Vela</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luc Frimat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dominique Chauveau</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Viktor Panescu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">François Glowacki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maxime Hoffmann</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maryvonne Hourmant</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dominique Besnier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Angelo Testa</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Philippe Zaoui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Charles Chazot</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laurent Juillard</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stéphane Burtey</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Adrien Keller</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nassim Kamar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Denis Fouque</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurice Laville</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Kidney International Reports</subfield><subfield code="d">Elsevier, 2016</subfield><subfield code="g">4(2019), 11, Seite 1546-1554</subfield><subfield code="w">(DE-627)881695580</subfield><subfield code="w">(DE-600)2887223-X</subfield><subfield code="x">24680249</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1546-1554</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ekir.2019.07.014</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2e2d670b48f24d0da27d45f04c41f401</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2468024919314354</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2468-0249</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2019</subfield><subfield code="e">11</subfield><subfield code="h">1546-1554</subfield></datafield></record></collection>
|
score |
7.4027834 |